Market Incident
Public · Developing
AI compiled from Infoway · 3 analyzed stories
Lupin Launches Raltegravir Tablets In United States
Lupin Limited launched Raltegravir Tablets, USP, 600 mg in the United States. The company announced the launch through a Reuters report, according to the supplied article.
Published:
Updated:
What happened
Lupin launched FDA-approved raltegravir 600 mg tablets in the United States. The tablets are a generic version of Merck’s Isentress HD and treat HIV-1. Lupin is the exclusive first-to-file company and is eligible for 180 days of generic exclusivity.
Global impact / market context
The launch gives Lupin a period of eligibility for exclusive generic sales. The reference product’s reported annual U.S. sales were estimated at $26 million, but no comparison with an earlier period was provided.
What to watch
- Check whether Lupin’s 180-day exclusivity begins and how long it lasts, because this affects the period when it may face generic competition.
- Check for reported sales of Lupin’s tablets, because the supplied information gives no sales results for the new launch.
- Check for updates on U.S. sales of the reference product, because the $26 million estimate has no earlier-period comparison.
Affected assets
- Lupin Limited
- Raltegravir Tablets USP, 600 mg
Evidence
- Infoway News — Lupin launches HIV drug in US, secures eligibility for 180-day generic exclusivity
- Infoway News — Lupin Limited (LUPIN) Launches HIV Generic With 180-Day Exclusivity
- Infoway News — Lupin Launches Raltegravir Tablets In United States
- Incident timeline — Lupin launches HIV drug in US, secures eligibility for 180-day generic exclusivity
- Incident timeline — Lupin Limited (LUPIN) Launches HIV Generic With 180-Day Exclusivity
- Incident timeline — Lupin Launches Raltegravir Tablets In United States